CRESCENT BIOPHARMA, INC. annual report, FY2022

Business context and reporting period

Filing identity: The request identifies Crescent BioPharma, Inc., but the supplied Form 10-K is for GlycoMimetics, Inc. (Nasdaq: GLYC). The filing covers the fiscal year ended December 31, 2022, not a standalone 2022 fourth quarter; quarterly results are not clearly provided in the supplied text.

GlycoMimetics is a clinical-stage biotechnology company developing glycomimetic drug candidates. Its lead candidate, uproleselan, is being studied with chemotherapy for acute myeloid leukemia (AML). The company had no approved products or product-sale revenue.

Financial and operating highlights

Revenue was primarily collaboration-related; the company reported no product sales. Gross or operating margins are not meaningful for this pre-commercial business. Research and development costs fell 40%, mainly because enrollment ended in the global Phase 3 and NCI-sponsored uproleselan trials and manufacturing costs declined. General and administrative expense rose 12%, including higher pre-commercialization and patent costs.

Net cash used in investing activities was $84,000; financing provided $4.16 million, principally from at-the-market (ATM) stock sales. Cash declined by $42.38 million during 2022. The filing reports no debt; year-end liabilities included $918,555 of current lease liabilities. Total lease payments remaining at December 31, 2022 were approximately $941,000, with the office lease scheduled to expire in October 2023.

Material changes and developments

• Uproleselan’s pivotal Phase 3 trial in 388 patients with relapsed/refractory AML reached its interim event threshold in late 2022. In February 2023, the independent monitoring committee recommended continuing to the planned final analysis, rather than unblinding early. Management projected the overall-survival trigger in the first half of 2024 and top-line data soon afterward.
• The Phase 2 portion of the NCI-sponsored trial in previously untreated older adults with AML completed enrollment of 267 patients in December 2021; an event-free-survival interim assessment was planned.
• The FDA cleared the GMI-1687 investigational new drug application for potential treatment of sickle-cell vaso-occlusive crisis in June 2022. GMI-2093 was selected for preclinical evaluation. GMI-1359 was no longer in active development; the company was seeking a licensing partner.
• The company sold 1.95 million shares through its ATM in 2022 for net proceeds of $4.16 million. After year-end and through the filing date, it sold a further 9.82 million shares for net proceeds of $28.7 million. Approximately $66 million remained available under the ATM at the filing date, creating potential for additional dilution.

Outlook, risks and unusual items

Management estimated that year-end 2022 cash, together with the $28.7 million of post-year-end ATM proceeds, would fund operations through the fourth quarter of 2024, excluding potential business-development proceeds and further financing. This is an estimate based on assumptions, and the company cautioned that it may use cash sooner than expected. It expects continued losses and requires additional capital; it has no committed external funding source apart from its ATM capacity and conditional Apollomics milestone and royalty payments.

Under its Greater China agreement, Apollomics is responsible for development and commercialization costs in that territory. GlycoMimetics may receive up to approximately $179 million in additional development, regulatory and commercial milestones and tiered royalties, but timing and achievement are uncertain. No Apollomics milestone revenue was recorded in 2022 or 2021.

• Clinical risk: Uproleselan is the only candidate in late-stage clinical development; pivotal efficacy and safety remain unproven. The monitoring committee’s recommendation to continue the trial is not a finding of efficacy.
• Funding and dilution: The company has an accumulated deficit of $419.6 million, depends on external financing, and may need to delay or reduce programs if capital is unavailable.
• Execution risks: Development depends on clinical-trial outcomes, regulators, collaborators and third-party manufacturers. GlycoMimetics has no manufacturing or commercial sales infrastructure of its own.
• Other disclosed matters: The filing states that Silicon Valley Bank was placed into receivership in March 2023 and that deposits were transferred to a bridge bank and made available in full. The company reported no material legal proceedings. The auditor issued an unqualified opinion on the financial statements; management reported effective disclosure controls and internal control over financial reporting. The auditor identified clinical-trial expense accruals as a critical audit matter because estimating work performed and costs incurred required judgment.

Important facts for investors to verify

1. Confirm the issuer: the supplied filing is GlycoMimetics, not Crescent BioPharma.
2. Track the timing and outcome of the uproleselan Phase 3 final analysis, projected for 2024, and distinguish the monitoring committee’s continuation recommendation from a positive trial result.
3. Review subsequent financing and share-count changes: the post-year-end ATM issuance materially increased shares outstanding and additional ATM sales were available.
4. Assess whether cash runway assumptions remain valid against trial, manufacturing, pre-commercialization and operating costs.
5. Check progress and funding implications of the NCI trial, GMI-1687 development and Apollomics programs, including whether any contingent milestones are achieved.